-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SQ6BtYqFM35/YGJKS8bSKKyB3g90Ci1iyMVlxPL+iaQ4/E5FgawZZDPBTp/ApHMN
 jUjvpYUoaCRUND4/vav/YA==

<SEC-DOCUMENT>0001193125-04-132056.txt : 20040805
<SEC-HEADER>0001193125-04-132056.hdr.sgml : 20040805
<ACCEPTANCE-DATETIME>20040805095238
ACCESSION NUMBER:		0001193125-04-132056
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20040804
FILED AS OF DATE:		20040805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN NV
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28564
		FILM NUMBER:		04953392

	BUSINESS ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
		BUSINESS PHONE:		31-77-320-8400

	MAIL ADDRESS:	
		STREET 1:		SPOORSTRAAT 50
		CITY:			KJ VENLO
		STATE:			P7
		ZIP:			5911
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 6-K </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Dated: August 4, 2004 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>QIAGEN N.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Spoorstraat 50 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>5911 KJ Venlo </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>The Netherlands </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;<FONT
FACE="WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&nbsp;&nbsp;<U></U></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Yes&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman"
SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#120;</FONT> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="toc"></A>QIAGEN N.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Form 6-K </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="1%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT><BR><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx68535_1">Other Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx68535_2">Signatures</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">
<A HREF="#tx68535_3">Exhibit Index</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx68535_1"></A>OTHER INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On August 4,
2004, QIAGEN N.V. issued a press release pursuant to Rule 135c announcing a proposed offering of US$150 million of senior unsubordinated convertible notes in reliance on Regulation S under the Securities Act of 1933, as amended. The press release is
furnished herewith as Exhibit 99.1 and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On August 4, 2004, QIAGEN N.V. issued a press release pursuant to Rule 135c announcing the pricing of a previously announced offering of US$150 million of senior unsubordinated convertible notes. The press release is
furnished herewith as Exhibit 99.2 and incorporated by reference herein. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx68535_2"></A>SIGNATURES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">QIAGEN N.V.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>EER</SMALL> M.
S<SMALL>CHATZ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Peer M. Schatz</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Chief Executive Officer</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Date: August 4, 2004</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>
<A NAME="tx68535_3"></A>EXHIBIT INDEX </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT><BR><HR WIDTH="63" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P><HR WIDTH="40" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release dated August 4, 2004</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release dated August 4, 2004</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>

</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 4, 2004
<TEXT>
<HTML><HEAD>
<TITLE>PRESS RELEASE DATED AUGUST 4, 2004</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g68535lo0g0-68535.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contacts: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Peer M. Schatz</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
FACE="Times New Roman" SIZE="2">QIAGEN N.V.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">+49 2103 29 11702</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">e-mail: <U>peer.schatz@QIAGEN.com</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dr. Solveigh M&auml;hler</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Investor Relations</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
FACE="Times New Roman" SIZE="2">QIAGEN N.V.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">+49 2103 29 11710</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">e-mail: <U>solveigh.maehler@QIAGEN.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>QIAGEN Announces
Offering of Convertible Notes </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>Venlo, The Netherlands,
August 4, 2004</B> - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) (&#147;QIAGEN&#148; or the &#147;Company&#148;) today announced that it plans to offer US$150 million of senior unsubordinated convertible notes (the &#147;Notes&#148;)
due 2024 to institutional investors outside the U.S. in reliance on Regulation S under the Securities Act of 1933, as amended. The Company also plans to grant the initial purchasers of the Notes an option to purchase up to an additional US$22.5
million aggregate principal amount of the Notes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Notes are
structured with a final maturity of 20 years, cannot be called for the first 7 years and are callable thereafter subject to a provisional call trigger of 120% of the conversion price. Noteholders will have an option to require the Issuer to redeem
the Notes at par at 7, 10, and 15 years. The Notes are to be offered with a coupon of 0.875% to 1.500% and a conversion premium of 45% to 50%. The coupon and conversion premium will be set at final pricing, which is expected to occur today.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">QIAGEN is launching the Notes to take advantage of the
attractive financing opportunities currently available in the convertible bond market. The offering will provide additional financial resources and flexibility while capitalizing on the current favorable market environment. The Company intends to
use a portion of the net proceeds for general corporate purposes, including the potential repayment or redemption of other outstanding debt and for potential acquisitions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Notes will be issued by a wholly-owned subsidiary of QIAGEN and guaranteed by QIAGEN. The settlement date of the Notes
is expected to be on or about August 18, 2004. An application will be made to list the Notes on the Luxembourg Stock Exchange. In conjunction with the offering of the Notes, a significant shareholder of QIAGEN may lend common shares to facilitate
execution of the offering </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Notes being offered and the common shares issuable upon conversion of
the Notes have not been registered under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and may not be offered or sold in the United </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>States absent registration or an applicable exemption from registration under the Securities Act and applicable state
securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><I>Stabilisation/FSA. </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>This announcement is for general information only and does not form part
of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement (the &#147;Securities&#148;) in certain jurisdictions may be
restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>This announcement is directed only at the following persons in the United Kingdom: persons having professional experience in matters relating to
investments; and persons falling within Articles 49(2)(a) to (d) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (high net worth corporations, unincorporated associations etc.). If you are in the United Kingdom
and do not fall into one of the above categories, any investment or investment activity to which this announcement relates is not available to you, and will not be engaged in with you, and you should not act upon, or rely on, this announcement.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Notes and (the rights to subscribe for) our common
stock are not and will not be offered, as part of their initial distribution or at any time thereafter, to persons who are established, domiciled or resident (&#147;</I><B>are resident</B><I>&#148;) in the Netherlands other than to persons who trade
or invest in securities in the conduct of their profession or trade (which includes banks, securities intermediaries (including dealers and brokers), insurance companies, pension funds, other institutional investors and commercial enterprises which
as an ancillary activity regularly invest in securities). The offer of the Notes and (the rights to subscribe for) our common stock, each announcement thereof and the prospectus that will be made available comply with the laws and regulations of
each State where persons to whom the offer is made are resident. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>The Notes and the common shares issuable upon conversion of the Notes have not been and will not be authorized for public offering in Luxembourg and may not be offered or sold in Luxembourg in circumstances that would constitute a public
offer unless the requirements of the Luxembourg law concerning public offers have been complied with. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the
Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, including statements regarding QIAGEN&#146;s intention to commence and complete the offering and the intended uses of the proceeds of any such offering. To the
extent that any of the statements contained herein are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and
synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN&#146;s, products
(including seasonal fluctuations), difficulties in successfully adapting QIAGEN&#146;s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from
competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC). </I></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>dex992.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 4, 2004
<TEXT>
<HTML><HEAD>
<TITLE>PRESS RELEASE DATED AUGUST 4, 2004</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT 99.2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g68535lo0g0-68535.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contacts: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Peer M. Schatz</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
FACE="Times New Roman" SIZE="2">QIAGEN N.V.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">+49 2103 29 11702</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">e-mail: <U>peer.schatz@QIAGEN.com</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Dr. Solveigh M&auml;hler</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Investor Relations</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT
FACE="Times New Roman" SIZE="2">QIAGEN N.V.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">+49 2103 29 11710</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">e-mail: <U>solveigh.maehler@QIAGEN.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>QIAGEN Announces
Pricing of $150 million of 1.5% Senior Convertible Notes Due 2024 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><B>Venlo, The Netherlands, August 4, 2004</B> - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) (&#147;QIAGEN&#148; or the &#147;Company&#148;) today announced the pricing of US$150 million of senior unsubordinated convertible
notes (the &#147;Notes&#148;) due 2024 sold to institutional investors outside the U.S. in reliance on Regulation S under the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Notes will be convertible into the Company&#146;s common shares at a conversion price of US$12.6449 (approximately
EUR10.53), subject to adjustment. The Notes will pay a coupon of 1.5%, payable semi-annually in arrears. At the time of pricing of the convertible bond on August 4, 2004 at approximately 1:00pm MET, the price for the Company&#146;s common stock was
approximately EUR 7.15 per share (approximately US$8.59 per share). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">QIAGEN is issuing the Notes to take advantage of the attractive financing opportunities currently available in the convertible bond market. The offering will provide additional financial resources and flexibility while capitalizing on the
current favorable market environment. The Company intends to use a portion of the net proceeds for general corporate purposes, including the potential repayment or redemption of other outstanding debt and for potential acquisitions. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Notes will be issued by a wholly-owned subsidiary of QIAGEN and
guaranteed by QIAGEN. The settlement date of the Notes is expected to be August 18, 2004. An application will be made to list the Notes on the Luxembourg Stock Exchange. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Roland Sackers, QIAGEN&#146;s Chief Financial Officer commented: &#147;We are pleased to have raised these funds at
attractive terms. This financing will contribute towards optimizing our balance sheet structure and puts us in a very strong position to execute our strategic plan.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Notes being offered and the common shares issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as
amended (the &#147;Securities Act&#148;) and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. This press release does not
constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful. </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT FACE="Times New Roman" SIZE="2"><I>Stabilisation/FSA. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any
offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement (the &#147;Securities&#148;) in certain jurisdictions may be restricted by law. Any persons reading this
announcement should inform themselves of and observe any such restrictions. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>This announcement is directed only at the following persons in the United Kingdom: persons having professional experience in matters relating to investments; and persons falling within Articles 49(2)(a) to (d) of
the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (high net worth corporations, unincorporated associations etc.). If you are in the United Kingdom and do not fall into one of the above categories, any investment or
investment activity to which this announcement relates is not available to you, and will not be engaged in with you, and you should not act upon, or rely on, this announcement. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Notes and (the rights to subscribe for) our common stock are not and will not be offered, as part of their initial
distribution or at any time thereafter, to persons who are established, domiciled or resident (&#147;</I><B>are resident</B><I>&#148;) in the Netherlands other than to persons who trade or invest in securities in the conduct of their profession or
trade (which includes banks, securities intermediaries (including dealers and brokers), insurance companies, pension funds, other institutional investors and commercial enterprises which as an ancillary activity regularly invest in securities). The
offer of the Notes and (the rights to subscribe for) our common stock, each announcement thereof and the prospectus that will be made available comply with the laws and regulations of each State where persons to whom the offer is made are resident.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The Notes and the common shares issuable upon
conversion of the Notes have not been and will not be authorized for public offering in Luxembourg and may not be offered or sold in Luxembourg in circumstances that would constitute a public offer unless the requirements of the Luxembourg law
concerning public offers have been complied with. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, as amended,
including statements regarding QIAGEN&#146;s intention to commence and complete the offering and the intended uses of the proceeds of any such offering. To the extent that any of the statements contained herein are forward-looking, such statements
are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of
currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market,
and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN&#146;s, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN&#146;s
products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For
further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC). </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>

</BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g68535lo0g0-68535.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g68535lo0g0-68535.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!9`&T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V1F"J68X`
MJDVH_,=D?'J34E^2+<8_O<UFYR:WIP35V)FK;W2SG;C:WI2W%RL`YY8]!6=;
MD_:(]OK3KPD7+YI^S7-8+DZZB=WS(,>QJW'(LD8=3\IK%!R:N0$_89MO3/\`
M^NG.FN@)DDNH!7*QJ&`[DT^"]$KA'7:QZ8/%9OX4H)R,=<U7LHV%<UYIE@3<
MWX#UJI_:39SY8Q]:;?[O-7/3;Q53CI4PIQ:NPN;$,RSIN7/N#4,UZL;[$&XC
MJ>U06!.Z0#/W:JY/([TE37,PN7XK\,0)%QGN*N5BCC/>M:#)@3/7:*FI!+5#
M0YT61"C#@UG26#(V!*F#TW'!I^MZB=+TUYT`,A.U`?4]Z\\FN9[B5I9Y7=R<
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M%BZ,%SU!Z5E>%]9DO+:6&ZD+O`-^\]2O_P!:N;U;6+G4[IG+LL(.$0'@#_&H
MIT*CJ-7V!M6.WAL`2'=U91V4YS5_I7FEAJEWI\PD@D(&<LN>&'TKT:WG6YMH
MYT^[(H8?C4XBE*#3;N@3,SQ/927NDGR@6>)MX4=2.]<!@\UZI++'!$\TKK'&
MBEF=C@*!U)->7ZS\3?!XOV6'2)K_``<-.@$:M].<FM\).;3BHW"1H^&["6\U
M>*1`?+@8.[]ACH*D\4V4EKJTLS`^7.=RMVSW%;GA#Q3H/B*S9=&Q"T7,ELZA
M77WQW'O4GBSQ+H?AZP!UEA()<^7;JNYY/H/ZT>VG[>W+Y6ZA96.$SQFNPTG1
M9V\+W44@*2W7SHIZC'3\\5R&F?$WP:+]?.T2>T4M\LS8D"^Y&>/UKU.VN8+R
MVCN;:5)895#)(AR&![BJQ52I&R<;`DCRQXVC=D="CJ<$$<BK.FV$VHWR01+G
M)&XX^Z.Y-6/%/Q'\(VE^UN;!]4GB.UY(<!0?3=GFM;P7XW\-:ZWV+3HC8W1&
M?L\J@%\>A'WJUG4J*GS\C%97%\96$BS0WB`F/9Y;$#[I'2N6)]:](UW6M,T+
M3'O-6F2.W'RX89+GT`[FO-$^)W@XW^3X>N1%G_6?*?QV9J,-.I*%E%NP-*YU
M_A#3)&@N;J52L<T9B3/<=S7-7EK+8W4EM,"&0X^OO7HND:II^LZ;%>Z9.DUL
MXPI7C;CL1V(]*Y7QEXZ\+Z/<&QO;<ZC=I]Z*(`^7]6[?2LZ56HZK7+OT[#:5
MC#MX)+F=(849W8X"CK7IEE;_`&2QAM\Y\M`I-</X2^(7A74;U;.&S;3+J4X3
MS0"'/H']?8UW]9XN<VU&2L$4<%\8KVXM?!JQ0L56YN5CE([K@G'Y@5X-FOJ+
MQ'H-KXET2?2[O*K*,JXZHPZ,*\/U'X5>++*Z,,-BM['GY9H9%PP]P2"*[LOK
MTXT^1NS%)%#X?WEQ9>.-*>W8@RSB)P/XD;@@_P`_PJS\3+RXO/'>HB<G%NXB
MC4]%4`8_/.?QKOOAW\,[C0[]=9UHI]JC!$%NAW",G@LQZ9QZ5/\`$7X;S>(K
MK^UM(:-;W:%EA<[1+CH0>QQQS5/%4?K-[]+7"SL>'$]*]-\)ZUJ%O\']?$3N
M/LK[(7[HKXW8^F2?QK"L_A5XNO+L12:>MJF<-+-*NT#UX))_"O9]#\'Z=H_A
M0^'ROGPS(PN'(P968<GV]O3`JL9B:7*E>^J!(^9CU]JLZ?=3V.H6UU;,4GAE
M5XRO4$&NTU[X1^(=.O7&FPC4;4GY'1@K@>C`GK]*VO!'PGOX]4AU+Q`B00P,
M'2U#!FD8=-V.`/;O71/%45#FYDQ69G_&B_N9_$-E:2;DACM5D5.VYB<G]`/P
MKSGKFOH;XA>!%\8V44MO(L.H6P(B9_NNIZJ?Z&O)U^%OC!KO[.=*"C./,,R;
M/SS6&$Q%+V*BW:PVM3>^#VI7=J-=AB)>-+,W"IV$B\#\_P"E>;S3R7$\D\KE
MY9&+NS=22<FOHGP)X*A\'Z5)%)(L]Y<D&XD`^7CHH]AD_7->?^+OA'J<.HRW
M?A^-;JTE8N(-X5XL]AG@CTJ*.*H^WF[VO;7T!IV/-`Q'()!'((KZ@\+W<]_X
M6TR[N<F::UC9R>I.!S^->1>&OA%K5]>QOK48L+-6RZEPTD@]`!G'U->WPQ1P
M0I#$@2.-0J*.@`X`K#,:U.=HQ=[#BA)YXK6WDGF<)%&I9V/0`5YS+XP\2^)]
M0DM?#5L8H$/,FT9QZLQX'TKI_'_F_P#"&WOE9_AW8_N[AFJOPU2W7PC&T('F
M-*YF(Z[L]_PQ7@U&Y5%!.R/8PT:='"RQ,HJ3O9)[+S.?F\1>-/"4\;ZU$+RT
M=L9.TY^C+T/UK6\6^,;BV\/:=JNASHJ7;D$N@;`QT(/0@U>\2ZQH>I^'M4LE
MOK>:6.!F,8;D,.GXYQ7FDWF_\()`&!\L:@_E_P#?`S^M85).%XQ=U8]+#4*>
M)<:E2FHM.S5K)IKL>Q:9J#2>'+;4;QQN-LLTK`8'W<DXKS6'XF:U_:\;S21?
M83/\T8B&1'GIGUQ6SXFU8V'PXTRSC;$M];QIQ_<"@M_0?C7/W>G:6GPYMF6]
MMCJ`F\]XQ(-^&XVXZ\#!_.BK4EHHO97)P6%HI2E5A?FERK3;?4].U_Q!::!I
M#:A,?,#8$2*?]8QZ`5PEKJOCWQ/NN]-_T>VR=A4*B'V!;DU@ZYJ\FJ^&=$26
M0M]F,D,GU&W!_P"^<?K7KOG1:=X=$]C#YT4%L&BC3^,!>`,>M6I>VD];)&,J
M*P%*/N*4Y-K796=OQ./\/^+/$5EKL>B>([*21Y>$E2/YE]SMX*^_:J^K^+/$
M_P#PE]SHVDO"Y$FV*,QKGIGJ?QJ2X^*%U;$&;P\\3$?+YDA7/YK7.7L^IR?$
M"2YTJ+&HNX:./@X)09'/'3-9RJ6BE&3>OS.NCA+U)3J4HQ]U]4XW77R1V.G7
MOCB#[9/K444=O%:2.C`(?W@&5Z&J?@OX@76I:H=.UJ2+=-Q!(JA1N_NGZ]JE
ML[CQH]OJ(U^(+9BQF((5!\VWC[O/K7&Z9X;EU3PO<ZM9;_M=E/DJIZI@'(]Q
MUHE.::Y;]=R:>'H5(5%545LDX[*_]:G>_$'Q+JGAX6/]FR1IYV_?OC#9QC'\
MZZVTD:6S@D?[SQJS?4BO%_$OB<^(='TQ;C(O+7>LQQP_3#?CBO9K#_D'6W_7
M%/Y"MZ53GG*STT/.QV%^KX:DI1M*\K^>N@^XMXKNVDMYT#Q2J5=3W!KSIO#/
MBCPE?2S^'I#=6LAYCX)]MRGJ1ZBO2J*UG34_4XL-BYT+Q23B]T]CQ?5=`\3Z
MM-<ZK<Z,T+`;I`B!,XZD+G)-;$^C7^N>!],L]-TB:"2UD/FI-\FXD?>!;&<F
MO4.]!K%8:*OKN=\LXJ-1M!+E>F]MK'F-]X3\0:SJ6F6]S9F&QM8(H&?S5.T`
M#><9ZYS^E="WPS\.,#^[N0>Q\X\5UM%:*A!7NKG//,\1))1?*EV/*],\`:HT
MMYIM];>7:R@F&Y#J=CK]UL9S@@D'ZU+9KX^\+)]@M[0WENG$>%\Q0/8Y!'T-
M>GT"H6'BOA;1K+-JL[^TA&2?1KKW/.-.\*Z_XEUF+4_%/[J"'!6`X!;';:.@
M]>]1ZIX;\30>-+G6M)LU/[PM$[.N""N.A->ET4_J\;6NR5FE53ORJUK6MHD<
M59?\)M>QWUMK%M$+>6TD5-FP$R$84<&I_AWHNH:)I-U!J-L8'>;<JE@<C:!V
MKKJ*M4DFG=NQA4QLITY4U%).VR['EGB[X>WYU9KC1+036\WS&,.%\MNXY/2O
D3K5&CM(48898U!'H<5+11"E&$FUU)Q&-JXBG"%3[/7K\S__9
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
